Press release
Segment Overview and Major Growth Areas in the End Stage Renal Disease (ESRD) Drug Market
End Stage Renal Disease (ESRD) Drug
Projected Growth and Market Size of the End Stage Renal Disease Drug Market
The ESRD drug market is expected to grow rapidly, reaching $262.76 billion by 2029. This growth represents a strong compound annual growth rate (CAGR) of 15.3%. Several factors contribute to this upward trend, including the development of new therapies, rising healthcare expenditures, the global increase in chronic kidney disease cases, the adoption of personalized medicine strategies, strong regulatory support, and faster drug approval processes. Key trends anticipated during the forecast period include a higher incidence of ESRD, improvements in treatment methods, a growing focus on precision medicine, the creation of combination therapies, and the integration of advanced technologies within healthcare.
Download a free sample of the end stage renal disease (esrd) drug market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Leading Companies Driving the End Stage Renal Disease Drug Market
Prominent players in the ESRD drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, and Merck Co. & KGaA.
In a notable development, Gore & Associates, a US-based materials science company, acquired InnAVasc Medical Inc. in August 2022 for an undisclosed sum. This acquisition enriches Gore's portfolio of dialysis access solutions with InnAVasc's graft technology designed to offer safer and more reliable access for dialysis patients, ultimately supporting better treatment outcomes. InnAVasc Medical Inc. specializes in technologies catering to patients with end-stage renal disease.
View the full end stage renal disease (esrd) drug market report:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report
Product Innovation as a Catalyst in the ESRD Drug Market
Innovation remains a driving force in the ESRD drug market, with companies heavily investing in novel therapies to maintain their competitive edge. For example, in April 2022, GlaxoSmithKline PLC announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) aimed at treating anemia related to chronic kidney disease. This therapy is inspired by Nobel Prize-winning research that unveiled how cells sense and adjust to oxygen availability, highlighting the cutting-edge nature of advancements in this field.
Detailed Breakdown of Segments in the End Stage Renal Disease Drug Market
This report segments the ESRD drug market into several key categories:
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, and Other Products.
2) By Indication: ESRD-induced Hyperparathyroidism, ESRD-induced Hyperphosphatemia, and ESRD-induced Hyperkaliemia.
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
4) By End User: Hospitals, Homecare, Specialty Clinics, and Other End Users.
Further subcategories include:
- Calcimimetics such as Cinacalcet and Etelcalcetide.
- Vitamin D variants including Calcitriol, Doxercalciferol, and Paricalcitol.
- Sterols like Ergocalciferol and Cholecalciferol.
- Potassium Binders such as Sodium Polystyrene Sulfonate, Patiromer, and Sodium Zirconium Cyclosilicate.
- Calcium-Based Phosphate Binders including Calcium Acetate and Calcium Carbonate.
- Other Products comprising Iron Supplements and Erythropoiesis-Stimulating Agents.
This comprehensive segmentation provides valuable insights into the diverse product and usage areas shaping the ESRD drug market's future.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Segment Overview and Major Growth Areas in the End Stage Renal Disease (ESRD) Drug Market here
News-ID: 4319491 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for ESRD
Driving End Stage Renal Disease (ESRD) Drug Market Growth in 2025: The Role of T …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
End Stage Renal Disease (ESRD) Drug Market Size Growth Forecast: What to Expect by 2025?
The market size for drugs treating end stage renal disease (ESRD) has seen a quick expansion in the recent past. The market, which was valued at $131.41 billion in 2024, is forecasted to reach $149.88 billion in 2025, displaying…
End Stage Renal Disease (ESRD) Drug Industry Report 2025-2034: Market Dynamics, …
The End Stage Renal Disease (ESRD) Drug Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current End Stage Renal Disease (ESRD) Drug Market Size and Its Estimated Growth Rate?
The market size for end-stage renal disease (ESRD) medications has witnessed a rapid upsurge…
End Stage Renal Disease (ESRD) Drug Market Report 2024 - End Stage Renal Disease …
"The Business Research Company recently released a comprehensive report on the Global End Stage Renal Disease (ESRD) Drug Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The…
End-Stage Renal Disease (ESRD) Market Share, Revenue, Prospects and Forecast 202 …
In recent years, the global End-Stage Renal Disease (ESRD) Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on End-Stage Renal Disease (ESRD) Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business…
End Stage Renal Disease (ESRD) Drug Market Size, Share, and Scope 2033
The new report published by The Business Research Company, titled ""End Stage Renal Disease (ESRD) Drug Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the end stage renal disease (esrd) drug market size has grown rapidly in recent years.…
End Stage Renal Disease (ESRD) Drug Market 2024-2033: Trends, Analysis & Growth …
The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $116.32 billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption…
